Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 394792, 7 pages
http://dx.doi.org/10.1155/2014/394792
Review Article

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future

1Department of Hematology, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto, Tokushima 770-8539, Japan
2Department of Hematology, Tokai Central Hospital, 4-6-2 Sohara-higashijima, Kakamigahara 504-8601, Japan

Received 2 December 2013; Accepted 14 January 2014; Published 20 February 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Shuji Ozaki and Kazuyuki Shimizu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Kyle, J. A. Child, K. Anderson et al., “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group,” British Journal of Haematology, vol. 121, no. 5, pp. 749–757, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Palumbo and K. Anderson, “Multiple myeloma,” The New England Journal of Medicine, vol. 364, no. 11, pp. 1046–1060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Alexanian, A. Haut, A. U. Khan et al., “Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens,” Journal of the American Medical Association, vol. 208, no. 9, pp. 1680–1685, 1969. View at Google Scholar · View at Scopus
  4. M. Attal, J.-L. Harousseau, A.-M. Stoppa et al., “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome,” The New England Journal of Medicine, vol. 335, no. 2, pp. 91–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Child, G. J. Morgan, F. E. Davies et al., “High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,” The New England Journal of Medicine, vol. 348, no. 19, pp. 1875–1883, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-L. Harousseau, M. Attal, H. Avet-Loiseau et al., “Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4621–4629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Sonneveld, I. G. Schmidt-Wolf, B. van der Holt et al., “Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial,” Journal of Clinical Oncology, vol. 30, no. 24, pp. 2946–2955, 2012. View at Google Scholar
  9. P. Sonneveld, H. Goldschmidt, L. Rosinol et al., “Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3279–3287, 2013. View at Publisher · View at Google Scholar
  10. A. Palumbo, S. Bringhen, T. Caravita et al., “Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial,” The Lancet, vol. 367, no. 9513, pp. 825–831, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” The New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. V. Rajkumar, S. Jacobus, N. S. Callander et al., “Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial,” The Lancet Oncology, vol. 11, no. 1, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Martinez-Lopez, J. Blade, M.-V. Mateos et al., “Long-term prognostic significance of response in multiple myeloma after stem cell transplantation,” Blood, vol. 118, no. 3, pp. 529–534, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Gay, A. Larocca, P. Wijermans et al., “Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients,” Blood, vol. 117, no. 11, pp. 3025–3031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Brenner, A. Gondos, and D. Pulte, “Recent major improvement in long-term survival of younger patients with multiple myeloma,” Blood, vol. 111, no. 5, pp. 2521–2526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Pulte, A. Gondos, and H. Brenner, “Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data,” Oncologist, vol. 16, no. 11, pp. 1600–1603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Pozzi, L. Marcheselli, A. Bari et al., “Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis,” British Journal of Haematology, vol. 163, no. 1, pp. 40–46, 2013. View at Google Scholar
  18. A. Palumbo, S. Bringhen, H. Ludwig et al., “Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN),” Blood, vol. 118, no. 17, pp. 4519–4529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Badros, B. Barlogie, E. Siegel et al., “Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years,” British Journal of Haematology, vol. 114, no. 3, pp. 600–607, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Palumbo, S. Triolo, C. Argentino et al., “Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients,” Blood, vol. 94, no. 4, pp. 1248–1253, 1999. View at Google Scholar · View at Scopus
  21. H. D. Klepin and D. D. Hurd, “Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?” Bone Marrow Transplantation, vol. 38, no. 9, pp. 585–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Mehta, M. Cavo, and S. Singhal, “How I treat elderly patients with myeloma,” Blood, vol. 116, no. 13, pp. 2215–2223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D. S. Siegel, K. R. Desikan, J. Mehta et al., “Age is not a prognostic variable with autotransplants for multiple myeloma,” Blood, vol. 93, no. 1, pp. 51–54, 1999. View at Google Scholar · View at Scopus
  24. B. Sirohi, R. Powles, J. Treleaven et al., “The role of autologous transplantation in patients with multiple myeloma aged 65 years and over,” Bone Marrow Transplantation, vol. 25, no. 5, pp. 533–539, 2000. View at Google Scholar · View at Scopus
  25. D. E. Reece, C. Bredeson, W. S. Pérez et al., “Autologous stem cell transplantation in multiple myeloma patients <60 vs 60 years of age,” Bone Marrow Transplantation, vol. 32, no. 12, pp. 1135–1143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Jantunen, T. Kuittinen, K. Penttilä, P. Lehtonen, E. Mahlamäki, and T. Nousiainen, “High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (65 years) myeloma patients: comparison with younger patients treated on the same protocol,” Bone Marrow Transplantation, vol. 37, no. 10, pp. 917–922, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma,” Bone Marrow Transplantation, vol. 39, no. 10, pp. 605–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. K. Kumar, D. Dingli, M. Q. Lacy et al., “Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis,” The American Journal of Hematology, vol. 83, no. 8, pp. 614–617, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. El Cheikh, E. Kfoury, B. Calmels et al., “Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma,” Hematology/Oncology and Stem Cell Therapy, vol. 4, no. 1, pp. 30–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Muta, T. Miyamoto, T. Fujisaki et al., “Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma,” Internal Medicine, vol. 52, no. 1, pp. 63–70, 2013. View at Google Scholar
  31. Q. Bashir, N. Shah, S. Parmar et al., “Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma,” Leukemia and Lymphoma, vol. 53, no. 1, pp. 118–122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Palumbo, S. Bringhen, M. T. Petrucci et al., “Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial,” Blood, vol. 104, no. 10, pp. 3052–3057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Facon, J. Y. Mary, C. Hulin et al., “Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial,” The Lancet, vol. 370, no. 9594, pp. 1209–1218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Barlogie, G. Tricot, E. Anaissie et al., “Thalidomide and hematopoietic-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 354, no. 10, pp. 1021–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Palumbo, F. Gay, P. Falco et al., “Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 800–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Gay, V. Magarotto, C. Crippa et al., “Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results,” Blood, vol. 122, no. 8, pp. 1376–1383, 2013. View at Google Scholar
  37. C. Straka, K. Schäfer-Eckart, F. Bassermann et al., “Prospective randomized trial of Len/Dex induction followed by tandem MEL 140 with autologous blood stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in myeloma patients age 60–75 years: protocol-defined safety analysis after 100 patients,” Blood, vol. 120, no. 21, 2012. View at Google Scholar
  38. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. K. Kumar, A. Dispenzieri, M. Q. Lacy et al., “Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients,” Leukemia, 2013. View at Publisher · View at Google Scholar
  40. S. Ozaki, T. Harada, T. Saitoh et al., “Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation: a multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network,” Acta Haematologica. In press.